Panbela Therapeutics, Inc. · OTC:PBLA
Panbela Therapeutics — Investor Presentation (September 2022)
37 slides from Panbela Therapeutics's investor presentation, September 2022
Slide 1: Combined Company Investor Presentation
Combined Company Investor Presentation September 2022 Last modified on 8/30/22 Panbela Therapeutics
Slide 2: Disclaimers
Disclaimers Certain statements in this presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are provided under the protection of the safe harbor for forward-looking statements provided by that Act. Forward-looking statements are b
Slide 3: Combined Company Presents A Unique Opportunity: Multi-Targeted Approach
Combined Company Presents A Unique Opportunity: Multi-Targeted Approach to Reset Dysregulated Biology Scientific focus on polyamines, key regulators of normal biology altered in many disease states 1 Multiple near term inflection points 2 Late-stage programs are orphan oncology related: pancreat
Slide 4: Highly Experienced Management Team with Proven Track Record
Highly Experienced Management Team with Proven Track Record Proven orphan and oncology drug discovery, development and commercialization expertise Dr. Jennifer Simpson Sue Horvath Rachel Bragg Chief Executive Officer Chief Financial Officer VP, Clinical Development 15+ Years 15+ Years 14+ Years Dr.
Slide 5: Dysregulation of the Polyamine Pathway Leads to Disease
Dysregulation of the Polyamine Pathway Leads to Disease Polyamine Dysregulation in Disease Cancer Pancreatic Autoimmune Diseases Familial Adenomatous Polyposis (FAP) Recent Onset Type 1 Diabetes Colorectal Ovarian STK11 Mutant NSCLC Neuroblastoma Initial focus on oncology and autoimmune disease - en
Slide 6: Combined Pipeline May Address Unmet Needs
Combined Pipeline May Address Unmet Needs Preclinical IND Ready Phase I Phase II Phase III Milestones PDA (First Line Metastatic) Phase III Ongoing; Interim Analysis Q1 2024 (Injection) SBP-101 PDA Neoadjuvant Phase II Ready – Open 2H 2022 Ovarian Phase I Ready – Open Early 2023 (eflornithine
Slide 7: Potential Market Opportunity for Lead Programs
Potential Market Opportunity for Lead Programs Pancreatic Cancer FAP Colorectal Cancer Ovarian Cancer Incidence of Incidence of Incidence of Incidence of 1L Metastatic Pancreatic Cancer FAP Colorectal Cancer Ovarian Cancer 57K in US ~30K in US ~150K in US ~22K in US ~190K in EU ~50K in EU ~340K in E
Slide 8: Complementary Pharmacotherapies Targeting Dysregulation
Complementary Pharmacotherapies Targeting Dysregulation Pipeline Objective Combined pipeline pharmacotherapies hit different targets in the polyamine pathway The objective of Panbela’s pipeline is the utilization of pharmacotherapies to reduce/normalize increased disease- CPP-1X-T & CPP-1X-S associa
Slide 9: SBP-101
SBP-101 Panbela Therapeutics 9
Slide 10: Preliminary Efficacy of SBP-101 + Gemcitabine/Nab-paclitaxel in First-Line Metastatic PDAC
Preliminary Efficacy of SBP-101 + Gemcitabine/Nab-paclitaxel in First-Line Metastatic Pancreatic Ductal Adenocarcinoma BEST OVERALL RESPONSE Overall Disease CR PR SD PD Response Control SBP-101 (0.40 mg/kg) + G/A* (Ph Ia COHORT 2) 0 5 (71%) 2 (29%) 0 5/7 (71%) 5/7 (71%) n=7 SBP-101 (0.40 mg/kg) + G/
Slide 11: Efficacy Comparison
Efficacy Comparison Treatment OS PFS ORR DCR PD CL-SBP-101-031 14.6 months 6.5 months 48.3% 82.8% 4.8% FOLFIRINOX2 11.1 months 6.4 months 31.6% 70.2% 15.2% Modified FOLFIRINOX3 10.2 months 6.1 months 35.1% 86.5% 13.5% Gemcitabine + Abraxane – 12.2 months 7.9 months 48% 68% 16% Phase 1/24 Gemcitabine
Slide 12: SBP-101 + Gemcitabine/Nab-paclitaxel Overall Survival
SBP-101 + Gemcitabine/Nab-paclitaxel Overall Survival* Cohort 2 N=7: 2 patients with long term survival. • One still alive at 33.1 months • One deceased at 30.3 months Cohort 4+1b = 6 patients still alive • One complete response (Recist) • One clinical complete response (no detectable tumor) * Data
Slide 13: Safety Results
SBP-101 + Gemcitabine/Nab-paclitaxel Demonstrated a Similar Safety Profile to Gemcitabine/Nab-paclitaxel in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Safety Results SBP- Grade ≥3 AEs of Special Interest N G+A %** Grade ≥3 adverse events attributable to any study medication, N=50. 101% H
Slide 14: Phase III Pancreatic Cancer Trial in Previously Untreated Metastatic PDAC
Phase III Pancreatic Cancer Trial in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma A Randomized, Double-Blind, Placebo Controlled Study of Nab-Paclitaxel and Gemcitabine with or Without SBP-101 OS-Overall Survival PFS-Progression Free Survival ORR – Overall Response R
Slide 15: FLYNPOVI: A combination of CPP-1X and Sulindac
FLYNPOVI: A combination of CPP-1X and Sulindac Panbela Therapeutics 15
Slide 16: Lead Product Opportunity – CPP-1X and Sulindac (Flynpovi)
Lead Product Opportunity – CPP-1X and Sulindac (Flynpovi) Familial Adenomatous Key Information: Polyposis (FAP) No approved FAP drugs on the market A genetic disease Target Physicians: Gastroenterologists caused by APC US-only potential revenue at market share of 35%-60% mutations where (app
Slide 17: FAP-310 Trial: Time to Delay FAP-related Event Endpoint
FAP-310 Trial: “Time to Delay FAP-related Event” Endpoint CPP FAP 310 global study 150 Patients Required (171 Patients Enrolled) Time to delay FAP-related events Composite Endpoint including surgeries, polyp removal, and 1:1:1 Randomization upper GI scoring system (“Spigelman”)*; based on FDA/EMA re
Slide 18: No Lower GI Surgeries for Flynpovi Combination
No Lower GI Surgeries for Flynpovi Combination Event Rate Distribution of FAP-Related Surgery Events in Lower GI Surgery Events ES Combo Eflornithine Sulindac Overall (N=56) (N=57) (N=58) (N=171) Need colectomy 0 3 4 7 Need proctectomy 0 1 1 2 Need pouch resection 0 4 1 5 Total Surgical Events 0 8 6
Slide 19: Flynpovi Combination Delays Need for Lower GI Surgery
Flynpovi Combination Delays Need for Lower GI Surgery Delay in Lower GI Surgery Events (Vertical hashmarks “|” denote when patient comes off study) 100 Subjects Event Free (%) 90 80 Treatment Groups 70 ES Sulindac 60 Eflornithine 50 0 6 12 18 24 30 36 42 48 Time from Randomization Date to FAP-relate
Slide 20: Rationale for Efficacy of Flynpovi in the Lower GI Tract of FAP Patients
Rationale for Efficacy of Flynpovi in the Lower Gastrointestinal Tract of FAP Patients Microbiome Diet MYC Growth/Tissue APC MAD1 ODC Put Polyamines Repair/Neoplasia K-RAS • Polyamines drive uncontrolled growth, polyposis, and cancer. • Polyamines can by synthesized but also derived from the diet an
Slide 21: High Concentrations of the Microbiota Contribute to the Impact of Polyamines in The LGI
High Concentrations of the Microbiota Contribute to the Impact of Polyamines in The LGI The microbiota increases steadily along the gastrointestinal tract. ◦ Small numbers in the stomach but very high concentrations in the colon. ◦ Areas of the LGI contain up to nine orders of magnitude (109) more
Slide 22: Adverse Events of Special Interest
Adverse Events of Special Interest Flynpovi (Eflornithine + Sulindac Sulindac Eflornithine Adverse Events of Special Interest Combination) N=57 N=56 N=56 Subjects (%) Subjects (%) Subjects (%) Anemia 1 (1.8) 5 (8.8) 2 (3.6) Myelosuppression 0 1 (1.8) 0 Thrombocytopenia 0 3 (5.3) 1 (1.8) Cardiovascul
Slide 23: Basis for FDA Complete Response Letter
Basis for FDA Complete Response Letter Clinical Single pivotal study efficacy was based on exploratory post-hoc analysis using a modified primary endpoint in a subgroup of the intent-to treat population o Asked to perform a new study focused on FAP patients with an intact lower- GI tract which s
Slide 24: Moving Ahead: New Phase III Trial
Moving Ahead: New Phase III Trial Moving Ahead 2022 North America Licensee funding next trial FDA and EMA focus on new Phase III trial: Lower GI focus (LGI), informed by positive data from FAP-310 and regulatory feedback Reaffirm current clarity & acceptable aspects of CMC, clin pharm, and n
Slide 25: Summary of Approach to Approval
Summary of Approach to Approval Strong Results in the Lower GI Focus on Lower GI: statistically significant p-values and hazard ratios for clinically meaningful surgical endpoints—emphasized by regulators—in Phase III pivotal trial Expected safety profile over 2-4 years of daily dosing in Phase
Slide 26: Polyamines & Immune Dysregulation
Polyamines & Immune Dysregulation Panbela Therapeutics 26
Slide 27: Role of Polyamines in Immune Dysregulation
Role of Polyamines in Immune Dysregulation Immune systems require multiple soluble and cellular components, including polyamines, for a normal immune function High levels of polyamines are present in tumor cells and in autoreactive B- and T-cells in autoimmune diseases Dysregulation of polyami
Slide 28: Rationale for Eflornithine/anti-PD-1 Combination
Rationale for Eflornithine/anti-PD-1 Combination Targeting Ornithine decarboxylase (ODC) using eflornithine unmasks antitumor T cell immune response by weakening of tumor-induced immune suppression that is mediated by Myeloid- Derived Tumor Suppressor Cells (MDSCs). The addition of anti-PD-1 pre
Slide 29: CPP-1X-S
CPP-1X-S Panbela Therapeutics 29
Slide 30: Rationale for CPP-1X-S (Eflornithine Sachets) in STK11 Mutant NSCLC
Rationale for CPP-1X-S (Eflornithine Sachets) in STK11 Mutant NSCLC In preclinical tumor models, eflornithine treatment improves anti-PD-1 efficacy by: Increasing tumor-specific cytotoxic T-cell populations Increasing expression of PD-1 on tumor-associated CD8+ T cells ~10% of NSCLC cancers
Slide 31: STK11 Mutant NSCLC Investigator-Initiated Trial
STK11 Mutant NSCLC Investigator-Initiated Trial Collaborating with investigators at Moffitt Cancer Center on Phase I/II trial: “Targeting Ornithine Decarboxylase as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient Non-Small Cell Lung Cancer” Patient Population Phase I Phase II Stage I
Slide 32: Business Overview
Business Overview Panbela Therapeutics 32
Slide 33: Barriers to Entry – Flynpovi/CPP-1X
Barriers to Entry – Flynpovi/CPP-1X Orphan status (7 years exclusivity US; 10 years exclusivity EU) for CPP-1X ◦ Granted in US and EU for FAP ◦ Granted in US and EU for Neuroblastoma ◦ Granted in US for Gastric cancer and Pancreatic cancer Pharmaceutical Composition Patent ◦ Fixed dose combinati
Slide 34: Barriers to Entry – SBP-101
Barriers to Entry – SBP-101 Orphan status (7 for years exclusivity US; 10 years exclusivity EU) for SPB-101 ◦ Granted in US for pancreatic cancer METHODS FOR PRODUCING (6S,15S)-3,8,13,18-TETRAAZAICOSANE-6,15-DIOL ◦ PCT application filed January 29, 2019 ◦ Granted in United States, India ◦ Pendin
Slide 35: Summary of Milestones
Summary of Milestones 2H 2022 Open- Phase I NSCLC Trial Open- Neoadjuvant Pancreatic Cancer Trial Open – Phase II Type I onset Diabetes Trial Publication of Phase I Type I onset Diabetes Data (2H 2022/1H 2023) Final Data – Phase I 1L mPC Gastric Cancer Prevention Phase II Results 1H 2023
Slide 36: Financial Position and Capital (unaudited)
Financial Position and Capital (unaudited) Panbela Cash at 6/30/22 2,530,000 Debt 6/30/22 Current (plus accrued interest) 1,716,000 Net of current portion 5,194,000 Common Stock at 6/30/22 20,774,045 Shares reserved for Options (WAE = $3.62) 4,040,890 Shares reserved for Warrants (WAE = 4.56) 5,447,
Slide 37: Summary: Combination of PBLA and CPP
Summary: Combination of PBLA and CPP Unique Scientific Approach: Resetting dysregulation via polyamine pathway Broad, late-stage de-risked pipeline opportunities Multiple partnerships supporting development programs Significant Market Potential Multiple data readouts expected Experienced Management
Panbela Therapeutics — Investor Presentation (September 2022) on 6ix